Company Overview

INVO Fertility, Inc. is a publicly traded fertility-focused healthcare company operating in the assisted reproductive technology (ART) and women’s health services industries. The company is best known for developing and commercializing the INVOcell® intravaginal culture system and for operating fertility clinics that provide infertility treatment services. Its primary revenue drivers include fertility treatment services delivered through owned and affiliated clinics, as well as limited product-related revenue tied to its proprietary fertility technology.

The company is positioned around expanding access to infertility care by offering lower-cost alternatives to traditional in vitro fertilization (IVF). INVO Fertility was founded to commercialize INVOcell®, a device that received U.S. FDA clearance and is designed to enable embryo incubation within the vaginal cavity. Over time, the company evolved from a product-centric model toward a clinic ownership and services model, reflecting a strategic shift to recurring healthcare service revenue and direct patient engagement.

Business Operations

INVO Fertility operates through fertility clinic services and related medical technologies. Its core operating focus is the ownership, management, and expansion of fertility centers operating under the INVO Centers model, which provide diagnostic services, infertility treatments, and IVF-related procedures. Service revenue from patient treatments represents the company’s primary source of income, while product-related revenue from INVOcell® has become secondary.

Operations are primarily domestic within the United States, with no verified material international clinic operations as of the latest public disclosures. The company controls proprietary medical technology associated with INVOcell® and operates clinics either directly or through affiliated physician practices. Public filings reference clinic acquisitions and management agreements, though details on joint ventures and long-term partnership structures are limited; some aspects of clinic-level ownership structures are data inconclusive based on available public sources.

Strategic Position & Investments

INVO Fertility’s strategic direction centers on scaling a clinic-based fertility care network focused on affordability, patient access, and geographic expansion within the U.S. The company has pursued growth through acquisitions of existing fertility practices and the rebranding of acquired assets under the INVO Centers platform. A notable acquisition includes The Fertility Center of California, which significantly expanded the company’s clinical footprint and patient volume.

The company continues to position INVOcell® as a differentiating technology, though recent disclosures emphasize clinic operations rather than device commercialization. Investment activity is primarily directed toward clinic integration, staffing, and operational infrastructure rather than early-stage technology development. Participation in emerging reproductive technologies beyond its core platform is not clearly substantiated; data inconclusive based on available public sources.

Geographic Footprint

INVO Fertility’s operations are concentrated in the United States, with clinical activities primarily located in California and select additional states through owned or affiliated fertility centers. The company’s corporate headquarters is reported to be in Florida, serving as the administrative and strategic base for its operations.

There is no verified evidence of material clinic operations or direct investments outside North America. While INVOcell® has historically been discussed in an international context, current operational influence appears domestic, with international market presence remaining limited or inactive based on public disclosures.

Leadership & Governance

INVO Fertility is led by an executive team with experience in healthcare services, medical devices, and public company management. The leadership emphasizes operational execution, clinic integration, and expanding access to fertility care. Governance follows standard U.S. public company structures, with oversight by a board of directors and compliance with SEC filings and Nasdaq reporting requirements.

Key executives include:

• Steve Shum – President and Chief Executive Officer
• Chris Kiszka – Chief Financial Officer
• Richard Waldman – Chief Operating Officer

Information regarding the original founder and early-stage leadership varies across public disclosures; data inconclusive based on available public sources.